AFM
CASI

Anson Funds Management’s CASI Pharmaceuticals CASI Stock Holding History

Anson Funds Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,751
Closed -$214K – 358
2021
Q4 		$214K Buy
+26,751
New +$266K 0.02% 302

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Anson Funds Management's CASI Position: Q1 2022 in Review

Anson Funds Management sold out of CASI Pharmaceuticals (CASI) in Q1 2022, closing a stake of 26,751 shares — an estimated $214K sold.

Anson Funds Management first reported a position in CASI in Q4 2021 and held it in 1 quarter. The position peaked at $214K in Q4 2021. 44 funds tracked by Wall St. Rank hold CASI as of Q1 2022.

  • Anson Funds Management reported no remaining CASI Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 26,751 CASI Pharmaceuticals shares in Q1 2022, an estimated $214K.
  • Anson Funds Management first reported a position in CASI Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's CASI Pharmaceuticals position peaked at $214K in Q4 2021.
  • 44 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.